Use of ramelteon for the treatment of secondary REM sleep behavior disorder

Internal Medicine

Volumn 52, Issue 18, 2013, Pages 2123-2126

  Nomura, Takashi ^a   Kawase, Shinya ^a   Watanabe, Yasuhiro ^a   Nakashima, Kenji ^a  

^a Division of Neurology   (Japan)

Author keywords

Melatonin; Multiple system atrophy; Parkinson's disease; REM sleep behavior disorder; REM sleep without atonia

Indexed keywords

AMANTADINE; CLONAZEPAM; CYSTEINE ETHYL ESTER TC 99M; ENTACAPONE; LEVODOPA; RAMELTEON; ROPINIROLE; SELEGILINE; THREO 3, 4 DIHYDROXYPHENYLSERINE; UNCLASSIFIED DRUG; ZONISAMIDE;

ADULT; AGED; ARTICLE; ATAXIA; BRAIN ATROPHY; CASE REPORT; DISEASE SEVERITY; DYSARTHRIA; ELECTROMYOGRAPHY; FEMALE; HUMAN; HYPERREFLEXIA; MALE; MOTOR COORDINATION; MYOCARDIAL PERFUSION IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASOMNIA; PARKINSONISM; PATHOLOGICAL REFLEX; QUESTIONNAIRE; SCORING SYSTEM; SHY DRAGER SYNDROME; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIDOR; TREMOR; URINARY DYSFUNCTION;

AGED; CLONAZEPAM; FEMALE; HUMANS; INDENES; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; POLYSOMNOGRAPHY; RECEPTORS, MELATONIN; REM SLEEP BEHAVIOR DISORDER; SLEEP APNEA SYNDROMES;

EID: 84884303547     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9179     Document Type: Article

References (17)

1. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 elder men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 46: 388-393, 1996.
2. American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed. Westchester, IL, 2005: 148-152.
3. Aurora RN, Zak RS, Maganti R, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med 6: 85-95, 2010.
4. Uchiyama M, Hamamura M, Kuwano T, Nishiyama H, Nagata H, Uchimura N. Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med 12: 119-126, 2011.
5. Rechtschaffen A, Kales A. A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages in Human Subjects. U.S. Government Printing Office, National Institute of Health Publication, Washington DC, 1968.
6. American Sleep Disorders Association. Manuals of the Scoring of Sleep and Associated Events. Rules, Technology, and Technical Specifications. 2007: 42-43.
7. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 8: 359362, 1998.
8. Nomura T, Inoue Y, Högl B, et al. Comparison of the clinical features of rapid eye movement sleep behavior disorder in patients with Parkinson's disease and multiple system atrophy. Psychiatry Clin Neurosci 65: 264-271, 2011.
9. Ghorayeb I, Bioulae B, Tison F. Sleep disorders in multiple system atrophy. J Neural Transm 112: 1669-1675, 2005.
10. Sixel-Doring F, Schweitzer M, Mollenhauer B, Trenkwalder C. Intraindividual variability of REM sleep behavior disorder in Parkinson's disease: a comparative assessment using a new REM sleep behavior disorder severity scale (RBDSS) for clinical routine. J Clin Sleep Med 15: 75-80, 2011.
11. Li SX, Wing YK, Lam SP, et al. Validation of a new REM sleep behavior disorder questionnaire (RBD-HK). Sleep Med 11: 43-48, 2010.
12. Sasai T, Matsuura M, Wing YK, Inoue Y. Validation of the Japanese version of the REM sleep behavior disorder questionnaire (RBDQ-JP). Sleep Med 13: 913-918, 2012.
13. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm 39 (Suppl): S 165-S172, 1993.
14. Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 4: 281-284, 2003.
15. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice of parameter: treatment of nonmotor symptoms of Parkinson disease: rep ort of the quality standards subcommittee of the American Academy of Neurology. Neurology 74: 924-931, 2010.
16. Rocchitta G, Migheli R, Esposito G, et al. Endogenous melatonin protects L-DOPA from autoxidation in the striatal extracellular component of the freely moving rat: potential implication for long-term L-DOPA therapy in Parkinson's disease. J Pineal Res 40: 204-213, 2006.
17. McCarter SJ, Louis EK, Boeve BF. REM sleep behavior disorder and REM sleep without atonia as an early manifestation of degenerative neurological disease. Curr Neurol Neurosci Rep 12: 182-192, 2012.